As cross-examination of Theranos investor Brian Grossman continued Wednesday, jurors heard more about the vetting Mr. Grossman's firm conducted before sinking $96 million into the blood-testing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback